Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd. (01349.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 2.52

From 52W high−34.59%

Volume1.88M

Market capHKD 2.71B

P/E (TTM)—

P/S (TTM)3.5x

Div yield—

Key dataSep 18, 2026

Open

HKD 2.52

From 52W high

−34.59%

Volume

1.88M

Market cap

HKD 2.71B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−11.1x

P/E (TTM)

—

RSI (14)

63.2

MomentumView details →

1D Return

+3.78%

YTD Return

−6.12%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−11.1x

EV/Sales

1.7x

P/S (TTM)

3.5x

P/B (TTM)

1.1x

ProfitabilityView details →

Gross Margin

87.34%

Net Margin

−18.66%

EBITDA Margin

−14.93%

ROE (TTM)

−5.77%

ROA (TTM)

−5.14%

Asset Turnover

0.28x

GrowthView details →

Revenue YoY

−3.82%

EPS YoY

—

FCF YoY

+491.24%

Revenue CAGR 3Y

−12.71%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+3.78%

YTD Return

−6.12%

1Y Return

−30.59%

RSI (14)

63.2

vs 50D SMA

+4.41%

vs 200D SMA

−4.95%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

6.53x

Quick Ratio

6.41x

Div Yield

—

Div Rate

—

Div Growth 1Y

−67.04%

EarningsView details →

EPS (Actual)

HKD 0.03

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

664.95M

Net Income (TTM)

−124.10M

Op. CF (TTM)

166.02M

Next earningsOct 22, 2026 →

Latest newsMore news →

Fudan Zhangjiang Bio-Pharmaceutical reported interim results for the six months ended June 2026, with net profit of 36.895 million RMB, up 545% year-on-year.37d ago

Similar companies

ST交昂600530.SH CF PharmTech, Inc.02652.HK Regencell Bioscience Holdings LimitedRGC Supernus Pharmaceuticals, Inc.SUPN Hua Medicine (Shanghai) Ltd.02552.HK 圣达生物603079.SH Find similar companies →

Latest newsMore news →

Fudan Zhangjiang Bio-Pharmaceutical reported interim results for the six months ended June 2026, with net profit of 36.895 million RMB, up 545% year-on-year.37d ago